Bionano Genomics Inc
Change company Symbol lookup
Select an option...
BNGO Bionano Genomics Inc
IGXT Intelgenx Technologies Corp
DGX Quest Diagnostics Inc
MDLZ Mondelez International Inc
FE FirstEnergy Corp
CADE Cadence Bancorp
SCHD Schwab U.S. Dividend Equity ETF™
ARKK ARK Innovation ETF
URANF International Prospect Ventures Ltd
QSR Restaurant Brands International Inc
Go

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Closing Price
$5.96
Day's Change
0.05 (0.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.95
Day's Low
5.79
Volume
(Heavy Day)
Volume:
74,919,044

10-day average volume:
25,597,890
74,919,044

Company Profile

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Company’s products include Sequencing for Discovery Research and Cytogenetics. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Company’s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
176.29x
Price/Book (MRQ)
29.13x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

March 2021
Current Month
28.6M
Previous Month
23.8M
Percent of Float
10.26%
Days to Cover
1.5935 Days

Share Information

BNGO is in a share class of common stock
Float
181.6M
Shares Outstanding
278.7M
Institutions Holding Shares
49
4.45%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • David L. BarkerChmn.
  • R. Erik HolmlinPres.
  • Christopher P StewartCFO
  • Mark OldakowskiCOO
  • Alka ChaubeyOther

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.